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Abstract 
 
Background 
Aneurysmal subarachnoid hemorrhage (aSAH) is the most prevalent form of hemorrhagic stroke 
and accounts for a large proportion of productive life years lost to stroke. Its surgical and 
medical treatment represents a multidisciplinary effort. Due to the complexity of the disease, the 
management remains difficult to standardize and quality of care is accordingly difficult to assess.  
Objective 
To create a registry to assess management parameters of patients treated for aSAH in 
Switzerland. 
Methods 
A cohort study was initiated with the aim to record characteristics of patients admitted with 
aSAH between January 1
st
 and December 31
st
 2009.  Ethical committee approval was obtained or 
is pending from the institutional review boards of all centers. In the study period, seven Swiss 
hospitals (five university (U), two non-university medical centers) harboring a neurosurgery 
department, an intensive care unit and an interventional neuroradiology team so far agreed to 
participate in the registry (Aarau, Basel (U), Bern (U), Geneva (U), Lausanne (U), St. Gallen, 
Zürich(U)).  Demographic and clinical parameters are entered into a common database. 
Discussion 
This database will soon provide (1) a nationwide assessment of the current standard of care and 
(2) outcome of patients suffering from aSAH in Switzerland. Based on data from this registry, 
we can conduct cohort comparisons or design diagnostic or therapeutic studies on a national 
level. Moreover, a standardized registration system will allow healthcare providers to assess the 
quality of care. 
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Introduction 
 
Overview and socioeconomic impact 
SAH is type of hemorrhagic stroke which occurs due to rupture of an intracranial aneurysm in 
85% of cases. The incidence of aSAH between regions of the world is highly variable (from 3 in 
parts of South America to over 20 per 100,000 person-years in Japan) (de Rooij, Linn et al. 
2007). aSAH represents 5% of all cerebrovascular accidents. In contrast to the more prevalent 
ischemic stroke which affects an older age-group, half of the patients suffering from aSAH are 
younger than 55 years. aSAH thus accounts for a quarter of all productive life years lost to stroke 
(Johnston, Selvin et al. 1998). Patients admitted and diagnosed with aSAH have long hospital 
stays (average in patients over 65 years: 22 days (Taylor, Yuan et al. 1997)) and most are at least 
temporarily monitored in a neuro-intensive care unit. The cost of hospitalization of a “low 
severity” case of aSAH was estimated to be 35,000$ in the US (Maud, Lakshminarayan et al. 
2009). The healthcare cost of aSAH amount to an estimated 437 million EUR per year for 
Germany alone (Dodel, Winter et al. 2010). In addition to the socioeconomic impact, the disease 
affects the quality of life of more than nine out of ten patients even one year after discharge 
(Meyer, Ringel et al. 2010).  
 
Necessity of a nationwide registry 
The management of aSAH in Switzerland has not been assessed on a national level to date.  We 
united large neurovascular centers in Switzerland to create a registry for aSAH. This registry 
helps collect clinical and management data from different centers and pools it in one common 
database. It may provide referring caregivers and healthcare providers with a critical tool to 
assess the quality of care in a disease which has a high socio-economic burden. Moreover, it may 
serve as a tool to foster scientific collaboration and address a number of remaining questions 
about the management of aSAH in the future. 
 
Dilemmas in the management of aSAH 
aSAH has a poor prognosis, with a mortality of about 40% and morbidity including neurological 
deficits affecting about one third of patients . Prognosis is not only limited by the bleed itself 
with the associated early brain injury, but also by conditions such as hydrocephalus, delayed 
ischemic neurological deficits and extracranial disease (Macdonald, Pluta et al. 2007). The 
following points briefly illustrate exemplary domains where further large-scale studies are 
necessary to answer imminent questions on the optimal management of aSAH. These and other 
points have been included in the current registry. 
 
Aneurysm treatment 
Rebleeding is the most dangerous complication of aSAH and occurs mostly within hours of days 
of the initial bleed. Therefore, it is mandatory to perform aneurysm treatment early to prevent re-
rupture. The main options for aneurysm occlusion are surgical clipping, endovascular coiling or 
stenting. The treatment decision is commonly taken after interdisciplinary discussion based on 
aneurysm size, location and the patient’s constitution. Surgical as well as interventional 
techniques have undergone significant development in recent years, prompting a continuous 
critical assessment of safety, efficacy and longterm outcome. Especially for stenting there is 
relatively little data to compare its risks and benefits to coiling or clipping. 
 
Management of hydrocephalus 
About 15% of patients develop acute hydrocephalus after aSAH (Graff-Radford, Torner et al. 
1989). The standard treatment for acute hydrocephalus cerebrospinal fluid drainage by an 
external ventricular drain. However, recent studies have re-assessed the possibility of lumbar 
drainage. The optimal management of subacute or late hydrocephalus still remains a matter of 
debate. Uncertainty also remains about the best timing to perform surgery for a ventriculo-
peritoneal shunt versus trying repeated lumbar punctures. 
 
Detection of delayed ischemic deficits 
Delayed ischemic deficits occur in a significant proportion of patients after aSAH and CT-
proven infarcts occur in 40% (Rabinstein, Weigand et al. 2005). It is suspected that the number 
of patients suffering cerebral ischemia after aSAH has been underestimated. Both the prevention, 
detection and the treatment of delayed ischemia remain unsolved problems: A number of 
diagnostic tools to monitor cerebral blood flow on the bedside are available, but their respective 
limitations have hitherto prevented universal acceptance (Vajkoczy, Horn et al. 2003). The main 
drawback of most bedside methods is their inability to monitor cerebral blood flow in the whole 
brain. Moreover, recent insights into alterations of cerebral blood flow due to waves of 
depolarization as precursors of ischemia may improve the early detection of delayed ischemic 
events. However, the development of practicable and widely available monitoring equipment is 
still in the experimental stages (Dreier 2011). 
 
Prevention of delayed ischemic deficits 
The fact that delayed ischemia after aSAH occurs several days after the bleed in patients who are 
already in the hospital makes this complication potentially preventable. Most of the early efforts 
in preventing these deficits were aimed at the treatment of angiographic cerebral vasospasm 
which occurs between days 4 and 14. Interestingly, the reduction of angiographic spasm has so 
far not translated to an improvement in patient outcome (Macdonald, Higashida et al. 2011). The 
calcium-channel blocker nimodipine has a modest impact on delayed cerebral ischemia and is 
the only pharmaceutical treatment approved for the treatment of delayed cerebral ischemia and 
vasospasm (Dorhout Mees, Rinkel et al. 2007). However, its side effects, particularly systemic 
hypotension, significantly limit its use in this patient population where therapeutic hypertension 
is mandatory. Local delivery of vasodilators such as nicardipine pellets was found to be of 
benefit in patients undergoing surgery for aSAHa (Barth, Capelle et al. 2007). 
 
Outcome measures 
aSAH for the larger part affects people in their working age. Therefore, even slight neurological 
disturbances can have a major impact on their ability to return to their previous occupation. 
Some authors argued that the presumed lack of efficacy for drugs reversing delayed cerebral 
vasospasm may be due to the absence of adequate outcome measures. Such outcome measures 
include a thorough neurological test battery as well as quality of life parameters. A registry on a 
national level could have a sufficient caseload to help develop and validate testing batteries 
including quality of life questionnaires such as the modified Rankin Scale or the Glasgow 
Outcome Scale Extended (Wilson, Pettigrew et al. 1998). Our hope is also that by standardizing 
outcome measures at a later point in this study, follow-up will ultimately improve. 
 
 
Materials and Methods 
Neurovascular teams at seven Swiss hospitals (five university (U), two non-university medical 
centers) which treat patients with aSAH held two initiation meetings in 2009 and 2010 (Aarau, 
Basel (U), Bern (U), Geneva (U), Lausanne (U), St. Gallen, Zürich(U)).  Participating centers 
have a neurosurgery department, an intensive care unit and an endovascular team and are tertiary 
referral centers within Switzerland. The Swiss SOS registry is designed as a multicentre database 
with the same parameters (an overview is provided in table 1, for a complete reference see 
supplementary material 1) which each participating center manages independently. Anonymized 
demographic and clinical data are recorded in prospective manner, or where necessary, 
retrospectively for cases admitted since 01.01.2009. Ethical committee approval was obtained or 
is pending from the institutional review boards of all centers. 
Patient recruitment 
All patients admitted with a diagnosis of aSAH at one of the participating centers are entered into 
the local database. Patient data is pseudonymized. The local databases can be fused into a 
common centralized file.  
Statistical analysis 
Statistical analysis and data quality evaluation will be performed by a dedicated statistician. 
 
Discussion 
Our aim is to create an observational database on clinical management aspects of aSAH. The 
severity of the disease and its many complications make aSAH a challenging disease to treat 
from the first day to the day where the patient can leave the hospital, often weeks later. aSAH 
patients can be categorized by clinical status at admission (World Federation of Neurological 
Surgeons Scale (Rosen and Macdonald 2005)), severity of hemorrhage (Fisher scale (Fisher, 
Kistler et al. 1980)), aneurysm localization, presence of hydrocephalus or epilepsy or even 
extracranial disease (e.g. cardiac arrhythmia, pulmonary edema). While all participating Swiss 
centers have a “high volume” (Barker, Amin-Hanjani et al. 2003) with more than 20 patients per 
year, but each patient requires individualized decision-making based on a multitude of 
parameters. Moreover, the patient is treated by a team including among others neurosurgeons, 
neuro-interventionalists, neuro-intensivists and anesthesiologists. The evident lack of consensus 
on optimal management prompts a large-scale effort which cannot be mustered by one center 
alone. For a population of about eight million, Switzerland has several neurovascular centers 
with a high standard, and a common Swiss registry can serve multiple purposes: 
Assessment of the status quo 
The management of patients with aSAH in Switzerland has not yet been explored on a national 
level. A common database will help provide such an assessment. 
Simplicity and standardization 
Our aim is to provide a database on aSAH which has a limited number of parameters and 
remains simple in its use. The parameters should be applicable in a similar manner by 
investigators from all centers and are therefore standardized.  
Socioeconomic parameters and patient outcome 
Age, duration of hospitalization (total duration and intensive care unit) and modified Rankin 
Scale at discharge as well as at follow-up are recorded in the database and give an estimate of the 
immediate socioeconomic burden of aSAH. Moreover, the database can be extended using 
quality of life measures. 
Clinical status and management 
Basic information on clinical status at admission, treatment modalities as well as delayed 
complications are recorded. The presence of multiple aneurysms and their impact on 
management can be derived from the datasets. 
Quality of care 
In response to increasing medical knowledge, medical disciplines are increasingly evolving 
towards areas of subspecialty. This tendency is also tangible in Switzerland where federal efforts 
are focused towards developing reference centers which are staffed and equipped appropriately 
and which will receive patients with a specific pathology from beyond their traditional 
recruitment area. 
Healthcare providers are also asked to justify expenses by documenting the quality of care. The 
ability to provide outcomes in a standardized manner will enable clinicians to anticipate requests 
of insurers and public institutions particularly. This is particularly important since the costs of 
neurointensive care management are high and medical evidence is often lacking to support our 
individually-based treatment decisions. 
Critical mass for research and further studies 
Swiss neurovascular centers traditionally have shown a strong interest in the improvement of 
patient care through scientific research. To unite several high-level neurovascular centers may 
improve the visibility of a geographically limited community with similar research interests. The 
coordination for larger-scale studies or translational research efforts could be facilitated.  
Funding  
Currently, the Swiss SOS is a loose framework of a “neurovascular interest group”. At present, 
no funding was applied for. As the first results of the collaboration will surface,  hypotheses for 
potential scientific applications will be discussed and funding will be applied for to answer 
specific questions or conduct a project of common interest. 
Limitations 
At the beginning, our database will be retrospective and observational. The assessed parameters 
(provided in table 1) are of relative simplicity in order to limit time and expenses for the 
investigators. In the first phase of the project, there will be no study nurse due to the lack of 
starting funds as described above.  
Conclusion 
The creation of a national network for aSAH is a logical step forward in documenting treatment 
and outcome for a complex disease. The first goal is the improvement of patient management by 
standardization and comparability. Furthermore, the registry may serve as an initiator for studies 
with scientific hypotheses regarding diagnosis and treatment of aSAH. 
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Table 1: Simplified overview of basic parameters 
 
 
